Trastuzuma (Herceptin) for HER2-positive early breast cancer

Recommendation by the National Health Care Institute [Zorginstituut Nederland] dated 10-09-2013, based on a re-evaluation by the WAR (Scientific Advisory Committee) after 4 years of provisional inclusion on the NZa Expensive Medicines Supervisory Rule.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.